Status and phase
Conditions
Treatments
About
This study will assess the immunogenicity and reactogenicity of the candidate GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine when administered to healthy subjects aged ≥ 15 years in Germany and ≥ 18 years in France compared to Boostrix™ and inactivated poliovirus vaccine administered separately, and with Revaxis®
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Absolute contraindications:
Precautions:
Primary purpose
Allocation
Interventional model
Masking
806 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal